This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

CRA Oncology experts
Industries

Oncology

Oncology consulting with cutting-edge strategies and comprehensive expertise

The treatment, policies, and study of oncology continue to undergo rapid changes and evolution, with each year bringing new opportunities and challenges for existing and new treatments. CRA positions itself on the cutting edge of the field, staying abreast of the latest issues and developments and allowing us to provide actionable, future-focused strategies for our clients.

CRA’s knowledge base stems from hundreds of engagements on solid and hematological tumors, working with clients on small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), cell therapies, oncology vaccines, and the increasing range of combination approaches to treating cancer.

Why CRA for your strategic partner in oncology?

Engagements

  • 01
    Demand study on impact of new treatments in small cell lung cancer (SCLC)
    CRA’s Life Sciences Practice was retained by a medium-sized pharmaceutical client to understand how the introduction of a small new cell lung cancer (SCLC)
    View engagement
  • 02
    Developing a pricing policy for oncology portfolio decisions
    A leading pharmaceutical company required support from CRA’s Life Sciences experts in developing a cross-functional ‘playbook’ to understand potential pricing
    View engagement
  • 03
    US go-to-market business strategy and market mapping for cell therapies in oncology
    A team of CRA Life Sciences consultants successfully assisted the client, an academic medical center (AMC), by using market research to identify key factors...
    View engagement
See More Oncology Engagements

Contact an Oncology expert.

See all Oncology experts

Latest insights

See All Oncology Insights

Recent events

See All Oncology Events

Subscribe to receive our latest Insights.

Subscribe